[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Health Research Institutes, Taiwan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":541},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,44,68,95,130,159,187,215,238,264,283,304,325,347,381,406,432,452,475,495,519],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":14,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100591531","phase-2-pegylated-liposomal-doxorubicin-pld-versus-active-surveillance-for-advanced-soft-tissue-sarcoma-patients-who-had-controlled-disease-after-standard-anthracycline-based-treatment-melody-100591531",false,"NCT06981637","Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)","Maintenance Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)","MELODY","Inclusion Criteria:\n\n1. A histologically confirmed advanced soft tissue sarcoma. Note that subtypes typically do not use chemotherapy as standard treatment are not allowed, such as alveolar soft part sarcoma, solitary fibrous tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma)\n2. Patients received first-line anthracycline-based treatment for a minimum of 4 cycles and a maximum of 8 cycles.\n3. The best response after first-line anthracycline-based treatment must be either a complete response, partial response, or stable disease as defined by RECIST 1.1.\n\n   The best response should be attributed solely to systemic treatment and not to local therapy. All the patients must have at least one measurable tumor based on RECIST 1.1 before initiating first-line anthracycline-based treatment.\n4. Patients must be randomized within 8 weeks of their last dose of anthracycline-based treatment\n5. Patients have a life expectancy ≥ 3 months\n6. Patients older than 18 years old.\n7. ECOG performance status of 0 to 1.\n8. Patients must have adequate organ function and marrow reserve measured within 7 days prior to randomization as defined below:\n\n   1. Hemoglobin ≥ 9.0 g\u002FdL;\n   2. Absolute neutrophil count ≥ 1,500\u002Fmm3;\n   3. Platelets ≥ 100,000\u002Fmm3;\n   4. Total bilirubin ≤ 1.5 x upper normal limit;\n   5. AST(SGOT)\u002FALT(SGPT) ≤ 2.5 x upper normal limit; for patients with liver metastases AST(SGOT)\u002FALT(SGPT) ≤ 5 x upper normal limit is allowed;\n   6. Serum creatinine ≤ 1.5mg\u002FdL or creatinine clearance ≥50ml\u002Fmin;\n   7. All women of childbearing potential must have a negative pregnancy test obtained within 72 hours before starting therapy.\n9. For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm.\n10. Patients with reproductive potential must use effective contraception (hormone orbarrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months after the completion of therapy.\n11. Patients must be able to comply with study procedures and sign informed consent.\n\nExclusion Criteria:\n\n1. Known allergy history to PLD or other drugs of liposome-based formulation.\n2. LVEF \\\u003C 50% at screening as determined by UCG or MUGA.\n3. Serious non-healing wound, ulcer, or bone fracture not related to underlying sarcoma.\n4. Major surgical procedure, open biopsy, significant traumatic injury, or radiotherapy within 21 days prior to randomization.\n5. Severe, uncontrolled medical conditions including severe liver disease, heart disease, uncontrolled diabetes or hypertension, or pulmonary disease.\n6. Psychiatric illness or social situation that would preclude study compliance.\n7. Women with pregnant or breast feeding (a urine pregnancy test must be performed on all female patients who are of childbearing potential before entering the study, and the result must be negative.\n8. Another previous malignancy diagnosed within the past 3 years. Patients with carcinoma in situ and stage I malignancy under active surveillance (no medical treatment needed) are allowed for enrollment.\n9. Active CNS metastasis defined by clinical symptoms, cerebral edema, steroid or anti- convulsant requirement, or progressive growth. Patients with a history of CNS metastasis or cord compression are allowed in the study if they have been treated and are clinically stable.\n10. Patients with active hepatitis B. However, patients with controlled hepatitis B under anti-viral agent are allowed.","ALL","18 Years",{"count":20,"type":21},81,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2",[26],"Advanced Soft Tissue Sarcoma",[28,29,30],"advanced soft tissue sarcoma","pegylated liposomal doxorubicin","open label randomized","RECRUITING","2026-07-01",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":35},"2025-12-31",{"date":39,"type":21},"2029-07-31",{"name":41,"class":42},"National Health Research Institutes, Taiwan","OTHER",7,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":43},"100479430","the-registry-study-of-genetic-alterations-of-oropharyngeal-cancer-in-taiwan-100479430","NCT05522881","The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan","Inclusion Criteria:\n\n1. Ages 20 and above\n2. Pathological reported as squamous cell carcinoma of head and neck\n3. Available p16 immunohistochemical staining status (restricted to the OPSCC subgroup)\n4. Participants have both archival tumor tissues from the primary head and neck SCC and from the first recurrent tumor (for the recurrence subgroup)\n5. Recurrence status is defined as the reappearance of the disease occurring more than 6 months following curative surgery and\u002For chemoradiotherapy in the recurrence subgroup\n6. Willingness to provide archival or newly obtained tumor tissues for current study proposal\n7. Life expectancy more than 3 months\n8. Patients fully understand the protocol with the willingness to have regular follow-up\n\nExclusion criteria\n\n1. Inability to cooperate by providing a complete medical history\n2. No available tumor tissues for genetic testing\n3. Undesirable compliance\n4. Having a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervical carcinoma in situ) that have undergone potentially curative therapy are not excluded","20 Years",{"count":52,"type":21},410,"OBSERVATIONAL","We will use the next-generation sequencing (NGS) technology to identify genomic alterations of Taiwanese HPV positive and negative oropharyngeal squamous cell carcinoma (OPSCC) for novel biomarker development and the study design of potential clinical trials or translational research.",[56],"Oropharyngeal Squamous Cell Carcinoma",[58,59,60,61],"human papillomavirus","oropharyngeal squamous cell carcinoma","next-generation sequencing","precision medicine",{"date":34,"type":35},{"date":64,"type":35},"2022-11-25",{"date":66,"type":21},"2029-12",{"name":41,"class":42},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},"100638334","quantitative-monitoring-of-disability-care-quality-for-long-term-care-facilities-2-100638334","NCT07579832","Quantitative Monitoring of Disability Care Quality for Long-Term Care Facilities 2","Inclusion Criteria:\n\n* Older adults with disabilities:\n\n  * Aged ≥ 65 years.\n  * Classified as CMS level 2-6 under Taiwan Long-Term Care Need Assessment.\n  * Currently receiving at least one Long-Term Care 2.0 service (e.g., home care, home-based rehabilitation, or respite care).\n  * Have normal cognitive function, or a Mini-Mental State Examination (MMSE) score ≥ 23 when cognitive screening is performed.\n  * Own and are able to use a smartphone.\n  * Willing to participate and provide written informed consent.\n* Family caregivers:\n\n  * Have normal cognitive function, or a Mini-Mental State Examination (MMSE) score ≥ 23 when cognitive screening is performed.\n  * Own and are able to use a smartphone.\n  * Willing to participate and provide written informed consent.\n* Multidisciplinary rehabilitation professionals:\n\n  * Employed or contracted by a home-based long-term care institution with at least three professional disciplines (e.g., physical therapists, occupational therapists, nurses, social workers).\n  * Own and are able to use a smartphone.\n  * Willing to participate and provide written informed consent.\n\nExclusion Criteria:\n\n* Older adults with disabilities:\n\n  * Severe acute medical conditions or unstable physiological status.\n  * Severe cognitive impairment without a caregiver capable of assisting with questionnaires.\n  * Not currently receiving any long-term care services.\n* Family caregivers:\n\n  * Severe acute medical conditions or unstable physiological status.\n  * Severe cognitive impairment without ability to complete questionnaires.\n  * Not currently involved in long-term care services.\n* Multidisciplinary rehabilitation professionals:\n\n  * Providing services exclusively in non-home-based settings (e.g., institutional or hospital-only care).","65 Years",{"count":76,"type":21},1080,[78],"NA","The goal of this clinical trial is to evaluate whether a smart wearable wristband-based care system can improve the quality of care and physical activity levels among older adults with disabilities receiving home-based care. The study population includes older adults with disabilities, their family caregivers, and multidisciplinary rehabilitation service providers.\n\nThe main questions it aims to answer are:\n\n1. Whether the use of a smart wearable wristband can improve functional performance, as measured by Activities of Daily Living (ADLs), Instrumental Activities of Daily Living (IADLs), and Integrated Care for Older People (ICOPE) assessments?\n2. Whether the intervention can increase physical activity levels and improve overall care quality, while reducing caregiver burden and enhancing satisfaction?\n\nParticipants will:\n\n1. Wear a smart wearable wristband continuously for 8 weeks to record physical activity data, including step count, activity level, heart rate, and fatigue index.\n2. Undergo assessments at baseline and after the 8-week intervention, including Activities of Daily Living (ADLs), Instrumental Activities of Daily Living (IADLs), Integrated Care for Older People (ICOPE), and the Chinese Version of the Physical Activity Scale for the Elderly (PASE-C).\n3. Provide data on caregiver stress, satisfaction, and service utilization for the analysis of care quality.",[81,82,83,84],"Disabled Persons","Activities of Daily Living","Aged","Motor Activity","NOT_YET_RECRUITING","2026-05-06",{"date":88,"type":35},"2026-05-12",{"date":90,"type":21},"2026-05-15",{"date":92,"type":21},"2027-12-31",{"name":41,"class":42},1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":17,"minAge":103,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":94},"100634471","social-prescribing-intervention-for-health-promotion-in-community-dwelling-older-adults-100634471","NCT07540117","Social Prescribing Intervention for Health Promotion in Community-Dwelling Older Adults","Social Prescribing for Health Promotion in Community-Dwelling Older Adults: Prospective Cohort Study Combining Mindfulness Meditation and Nordic Walking Pole Exercise","Inclusion Criteria:\n\n* Adults aged 55 years and older\n* Community-dwelling older adults\n* Able to walk independently or with assistive devices\n* Normal cognitive function or mild cognitive impairment, with ability to understand and follow study procedures\n* Willing to sign informed consent\n* Willing to participate in the intervention and complete study assessments\n\nExclusion Criteria:\n\n* Major surgery or hospitalization within the previous 3 months\n* Severe cardiovascular disease or other medical condition making exercise inappropriate, based on physician assessment\n* Moderate to severe dementia or other severe psychiatric disorder\n* Inability to comply with the 4-week mindfulness meditation program or the 12-week walking-pole exercise program",true,"55 Years",{"count":105,"type":21},1500,[78],"This study evaluates the effects of a social prescribing intervention on health promotion outcomes in community-dwelling older adults. The intervention consists of a 4-week mindfulness meditation program followed by a 12-week walking-pole exercise program. The purpose of the study is to determine whether this combined intervention improves physical function, psychological well-being, and sleep quality.\n\nEligible participants aged 55 years and older will be enrolled from community settings and will receive the same 16-week intervention. Assessments will be conducted at baseline, after the mindfulness phase, after completion of the full intervention, and 3 months after the intervention ends. Study outcomes include physical function, mood, well-being, sleep quality, and indicators of continued participation and lifestyle change.\n\nThe investigators hypothesize that the combined social prescribing intervention will lead to improvements in physical and psychological health among community-dwelling older adults and support healthy aging.",[109,110,111],"Aging","Health Promotion","Mental Health",[113,114,115,116,117,118,110,119,120,121],"Social Prescribing","Mindfulness Meditation","Walking Pole Exercise","Older Adults","Community-Dwelling Older Adults","Healthy Aging","Psychological Well-Being","Sleep Quality","Physical Function","2026-04-20",{"date":124,"type":35},"2026-04-23",{"date":126,"type":35},"2026-04-14",{"date":128,"type":21},"2029-04",{"name":41,"class":42},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":102,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":137,"targetDuration":138,"studyType":53,"phases":4,"briefSummary":139,"conditions":140,"keywords":143,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":94},"100634581","adult-disease-risk-prediction-using-wearables-hearing-and-health-data-100634581","NCT07541547","Adult Disease Risk Prediction Using Wearables, Hearing, and Health Data","A Study to Build a Disease Risk Prediction Model for Adults by Integrating Data From Wearable Devices, Hearing Tests, and Multiple Health Databases","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Living in the community in Taiwan\n* Able to understand the study procedures and provide written informed consent\n* Able and willing to complete the study questionnaire, hearing assessment, and wearable device monitoring procedures\n* Has access to a smartphone and is able to install and use the study-related application, with assistance from study staff if needed\n\nExclusion Criteria:\n\n* Diagnosis of dementia\n* Too frail or has other health conditions that make participation in the study procedures not feasible\n* Bilateral deafness without use of any hearing assistive device\n* Does not have a smartphone or is unable to use a smartphone application required for the study procedures",{"count":105,"type":21},"2 Weeks","This prospective cohort study aims to develop and validate a personalized disease risk prediction model for adults by integrating multiple sources of health data. The study will recruit community-dwelling adults aged 18 years and older in Taiwan. After providing informed consent, participants will complete a structured questionnaire, undergo pure tone hearing testing, and wear a smartwatch for 2 weeks to collect continuous physiological data, including heart rate and physical activity. With participant authorization, the study will also collect data from personal health records and national health insurance databases to allow longer-term follow-up of health outcomes.\n\nThe main goals of the study are to examine the relationships among hearing, lifestyle factors, and wearable device data; to identify combinations of risk factors associated with progression from health to subclinical or chronic disease states; and to develop analytical methods for integrating heterogeneous health data from questionnaires, physiological monitoring, hearing tests, and medical databases. Machine learning methods will be used to identify important predictors and build risk prediction models.\n\nThe study hypothesis is that combining hearing measures, lifestyle information, wearable physiological data, and longitudinal medical record data will improve the ability to identify individuals at higher risk of future disease compared with using a single source of information alone. The long-term objective is to support early risk identification, personalized health management, and prevention strategies in community adults.",[141,142],"Chronic Disease","Risk Assessment",[144,142,141,145,146,147,148,149,150],"Wearable Devices","Disease Prediction","Machine Learning","Cohort Studies","Physiological Monitoring","Personal Health Records","Health Insurance Claims","2026-04-13",{"date":153,"type":35},"2026-04-21",{"date":155,"type":35},"2026-01-09",{"date":157,"type":21},"2029-01",{"name":41,"class":42},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":74,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":186,"locationsCount":94},"100536928","strategic-lifestyle-intervention-for-metabolic-syndrome-slim-met-100536928","NCT06271200","Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET)","Effects of Intensive Lifestyle Interventions (ILI) on Weight Loss and Cardiometabolic Risks in Obese Adults With Metabolic Syndrome: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Men or women aged from ≥ 20 years to 65 years\n* BMI 27.0 to 45.0 kg\u002Fm2 with metabolic syndrome by IDF definition\n\nExclusion Criteria:\n\n* History of HIV, hepatitis B or C (self-report) or active pulmonary tuberculosis\n* Diagnosis of type 1 or type 2 diabetes and regular taking oral or injection hypoglycemic therapy\n* History of malignant tumors with active managements.\n* History of medullary thyroid carcinoma or diagnosis of multiple endocrine neoplasia syndrome type 2 (MEN 2)\n* Serious liver dysfunction or chronic kidney disease (aspartate aminotransferase (AST) or alanine transaminase (ALT) \\> 3 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin\u002F1.73 m2)\n* History of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 6 months History of severe gastrointestinal diseases or gastrointestinal surgery in the past 6 months\n* History of Cushing's syndrome, hypothyroidism, acromegaly, hypothalamic obesity without regular managements.\n* History of hypersensitivity to semaglutide or any component of RYBELSUS®, or history of severe hypersensitivity reactions to Forxiga, such as anaphylaxis or angioedema.\n* Taking medications affecting weight or energy intake\u002Fenergy expenditure in the last 3 months, including weight loss medications, antipsychotic drugs or other medications as determined by the study physician\n* Currently participating in weight loss programs or weight change in the past 3 months (\\>5% current body weight)\n* Women who are pregnant or plan to become pregnant\n* Patients who cannot be followed for 3 years (due to a health situation or migration)\n* Patients who are unwilling or unable to give informed consent",{"count":167,"type":21},200,[78],"This study is a randomized, parallel-group, observer-masked clinical trial. A total of 200 obese participants with MetS will be enrolled. Eligible subjects will be randomly assigned to the ILI group or ULI group with an allocation ratio of 2:1. The ILI group will be instructed to eat in 8 hours while fasting in 16 hours on daily basis over 24 weeks. Furthermore, enhanced daily physical activities with walking more than 10,000 steps will be implemented. The enrolled participants will be instructed to follow a diet with reduction of daily intake of 500 kcals per day. ILI group will be asked to use the Health2Sync mobile app to track self-measured outcomes and daily diet control. The investigators objectively measure step counts for participants of ILI group during 24-week intervention period using a wearable device (Fitbit Inspire 2). Participants are asked to attach the pedometer on their waist belt, except while bathing and sleeping. The ULI group will be instructed to follow habitual meal timing. In addition, all participants of both groups will receive the health education. Anthropometric, sociodemographic data, biochemical variables, and metabolic variables will be measured at baseline and during follow-up visit. DEXA and MRI of abdomen will be measured at baseline and during following up visits. The proposed trial is designed to provide 85% statistical power to detect a significant difference in changes in the metabolic syndrome severity score after reduction \\> 5% body weight over 24 weeks.\n\nAfter completion of the initial 24-week lifestyle intervention, which often has limited weight loss efficacy when used alone, a second-phase intervention will be conducted from week 26 to week 52. Participants in both the ILI and ULI groups will be randomly assigned in a 1:1 ratio to receive one of two evidence-based oral weight control medications: a GLP-1 receptor agonist (Rybelsus) or an SGLT-2 inhibitor (Forxiga), for a duration of 26 weeks. The ILI group will continue with the daily 8-hour time-restricted eating and 16-hour fasting regimen, along with walking more than 10,000 steps per day. This phase aims to evaluate the effects of these two medications on weight reduction and liver fat content, with or without prior 26-week intensive lifestyle intervention. After the 26-week medication intervention, all participants will be followed for an additional 52 weeks to assess the sustainability of weight loss.",[171],"Metabolic Syndrome",[173,174,175,176,177,178,179],"Weight loss","Intermittent fasting","10,000 steps","Mobile App","Continuous glucose monitoring (CGM)","GLP-1 receptor agonist","SGLT-2 inhibitor","2026-04-07",{"date":182,"type":35},"2026-04-08",{"date":184,"type":35},"2024-03-14",{"date":92,"type":21},{"name":41,"class":42},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":102,"sex":17,"minAge":195,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":198,"conditions":199,"keywords":203,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":94},"100604580","plant-based-diets-and-healthy-aging-100604580","NCT07151365","Plant-based Diets and Healthy Aging","Plant-based Diets and Healthy Aging - the Tzu Chi Aging Study (TCAS)","TCAS","Inclusion Criteria:\n\n* Age 40 years or older.\n* Volunteers of the Tzu Chi Foundation.\n* Participating in the 2-day comprehensive health examination program.\n\nExclusion Criteria:\n\n* Pregnant individual.\n* Diagnosed with dementia or poor cognition resulting in inability to answer questionnaires.","40 Years",{"count":197,"type":21},5000,"This prospective study investigates the health effects of vegetarian and plant-based diets in middle-aged and older adults in Taiwan, specifically, recruiting 5000 Tzu Chi volunteers. Previous Tzu Chi cohorts found vegetarian diets were protectively associated with incidences of diabetes, stroke, gout, cataracts, insomnia, and gallstones, while reducing healthcare costs. The study also aims to clarify dietary patterns-particularly plant-based and vegetarian diets-and determine how potential deficiencies or excesses of various nutrients influence common aging-related health issues, including healthy cognitive decline, sarcopenia, and the risk of age-related diseases, in order to inform dietary and lifestyle recommendations that promote healthy aging and maintain physical function.",[118,200,201,202],"Sarcopenia","Frailty","Cognitive Decline",[204,205,206,207,200,201],"Vegetarian diets","Plant-based diets","Healthy aging","Cognitive decline","2026-04-06",{"date":182,"type":35},{"date":211,"type":35},"2025-09-01",{"date":213,"type":21},"2028-12-31",{"name":41,"class":42},{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":221,"minAge":18,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":237},"100525877","the-registry-of-genetic-alterations-of-taiwan-ovarian-cancer-100525877","NCT06127446","The Registry of Genetic Alterations of Taiwan Ovarian Cancer","Inclusion Criteria:\n\n1. Age 18 and above.\n2. Stage I to IV high grade serous or clear cell carcinoma of ovary, peritoneal and fallopian tube.\n3. Patients with primary ovarian cancer had undergone primary surgery. Patients with recurrent ovarian cancer had undergone primary surgery (and biopsy\u002Fsurgery for recurrent tumors).\n4. Tumor tissues before neoadjuvant therapy will be collected for patients receiving surgery after any neoadjuvant treatment.\n5. Willingness to provide the surgical tissues of primary tumors, non-tumor part normal tissue (and paired recurrent tumors in 80 patients).\n6. Willingness to provide blood sample of 20ml within four weeks after registration (in at least 72 patients of primary ovarian cancer and 72 patients of recurrent ovarian cancer).\n7. Patient fully understand the protocol with the willingness to have regular follow-up.\n8. Life expectancy more than 3 months.\n\nExclusion Criteria:\n\n1. Concomitant ovarian and endometrial cancer\n2. Paraffin tissue tumor block older than five years.\n3. Tumor specimen of primary surgery or recurrent biopsy\u002Fsurgery are not qualified for genetic testing.\n4. Concomitant malignancy under surveillance or treatment in the past three years (excluding curatively treated basal or squamous cell skin carcinoma or carcinoma in situ)\n5. Inability to cooperate or undesirable compliance to the study.","FEMALE",{"count":223,"type":21},300,"Despite recent progress in chemotherapy and targeted therapy for ovarian cancer, the 5-year survival rate remains around 40% because of rapid development of treatment resistance and recurrence. The sensitivity to platinum agents or BRCA genes mutation has been the prerequisite for improved survival using PARP inhibitors, though only 15-20% ovarian cancer patients harbor BRCA mutations through germline or somatic variants. Bevacizumab can only delayed disease recurrence but failed to improve overall survival. Several approved cancer therapeutics with established safety and toxicity profiles should be assessed in the immediate future based on biomarkers of platinum resistant, BRCA wild type recurrent ovarian cancer.\n\nFurthermore, the proportion high grade serous and clear cell adenocarcinoma of ovary cancer in Taiwan increased substantially in recent 10 years. Genetic factors (such as homologous recombination deficiency, mismatch repair genes mutation), environmental factors (such as oral contraceptives, nulliparity\u002Flow parity) as well as comorbidity including endometriosis may be associated with the changing pattern and clinical outcomes of ovarian cancer in Taiwan.\n\nNext-generation sequencing technology has enabled cancer genome sequencing in screening and searching for new cancer genes in an efficient manner. This massive sequencing technique not only help to identify new altered genes for novel biomarker development, but also reveal gene alterations sensitive or resistant to specific therapies.\n\nThe specific aims of this project are (1) to systemically explore genomic profiling of Taiwanese primary or platinum-resistant or -sensitive recurrent (or recurrent) ovarian cancer focusing on high grade serous and clear cell adenocarcinoma; (2) to collect clinical data regarding comorbidity, survival time and responses to major types of anticancer therapy; and (3) to establish a comprehensive ovarian cancer cohort for additional translational studies. The long-term goals of this study are to help implement personalized therapy, to develop novel therapy, and to improve outcomes of patients with ovarian cancer.",[226],"Ovarian Cancer",[228,229],"ovarian cancer","Next generation sequencing",{"date":231,"type":35},"2026-04-09",{"date":233,"type":35},"2023-12-13",{"date":235,"type":21},"2031-12-31",{"name":41,"class":42},8,{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":245,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":250,"conditions":251,"keywords":255,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":263,"locationsCount":94},"100510547","phase-1-ramucirumab-cyramza-nal-iri-onivyde-and-trifluridinetipiracil-lonsurf-in-second-line-metastatic-gastric-cancer--100510547","NCT05927857","Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine\u002FTipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .","A Phase Ib\u002FII Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine\u002FTipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).","Inclusion Criteria:\n\n1. histologically or cytologically confirmed metastatic gastric adenocarcinoma\n2. patients have received only first line of systemic therapy, including recurrence during adjuvant therapy or within 6 months after the completion of adjuvant treatment.\n3. ECOG(Eastern Cooperative Oncology Group) performance status 0 or 1\n4. patients with HER2\u002Fneu-positive tumor must be exposure to Herceptin treatment\n5. at least one measurable disease according to the RECIST version 1.1;\n6. patients are aged 20 to 80 years;\n7. patients have a life expectancy ≥ 3 months;\n8. patients have adequate renal function with defined as serum creatinine ≤ 1.5 times the upper limit of normal (ULN) or Ccr ≥ 40 mL\u002Fmin;\n9. patients with adequate hepatic function as defined by a total bilirubin ≤1.5 times the ULN, and aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 times the ULN or 5 times the ULN in the setting of liver metastases.\n10. patients have adequate bone marrow function, defined as an absolute neutrophil count ≥ 1500\u002Fmm3, hemoglobin ≥9 g\u002FdL, and platelet count ≥ 100,000\u002Fmm3 (transfusion or G-CSF support before enrollment is allowed)\n11. patients have International Normalized Ratio (INR) ≤1.5 and a partial thromboplastin time (PTT) (PTT\u002FaPTT) \\\u003C 1.5 x ULN;\n12. patients' urinary protein is ≤1+ on dipstick or routine urinalysis or a 24-hour urine collection for protein must demonstrate \\\u003C1000 mg of protein if urine dipstick or routine analysis is ≥ 2+;\n13. patients with childbearing potential shall have effective contraception for both the patient and his or her partner during the study;\n14. female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dose of protocol therapy;\n15. the ability to understand and willingness and to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. patient can't take oral drugs;\n2. known hypersensitivity to irinotecan, fluoropyrimidine, or ramucirumab;\n3. receipt of surgery within the past 4 weeks before study enrollment;\n4. ≥ grade 2 diarrhea and ascites\n5. concurrent severe infection with intravenous systemic antibiotics treatment;\n6. patients have experienced any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within 6 months prior to first dose of protocol therapy;\n7. patients have a prior history of GI perforation\u002Ffistula (within 6 months of first dose of protocol therapy) or risk factors for perforation;\n8. patients have:\n\n   * cirrhosis at a level of Child-Pugh B (or worse) or\n   * cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis;\n9. patients have a serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to first dose of protocol therapy;\n10. patients have undergone major surgery within 28 days prior to first dose of protocol therapy, or minor surgery\u002Fsubcutaneous venous access device placement within 7 days prior to the first dose of protocol therapy. Patients have elective or planned major surgery to be performed during the course of the clinical trial;\n11. patients have uncontrolled or poorly-controlled hypertension (\\>160 mmHg systolic or \\> 100 mmHg diastolic for \\>4 weeks) despite standard medical management;\n12. patients have experienced any grade 3-4 GI bleeding within 3 months prior to first dose of protocol therapy;\n13. patients have a history of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered \"significant\") during the 3 months prior to first dose of protocol therapy;\n14. patients are receiving chronic antiplatelet therapy, including dipyridamole or clopidogrel, or similar agents. Once-daily aspirin use (maximum dose 325 mg\u002Fday) is permitted;\n15. previously received prior nal-IRI (ONIVYDE®) or TAS-102 (LONSURF®) or ramucirumab therapy\n16. another previous malignancy diagnosed within the past 5 years except for non melanoma skin cancer or stage I cervical cancer;\n17. pregnant or breast feeding women.","80 Years",{"count":247,"type":21},45,[249,24],"PHASE1","Primary Objectives\n\n* In phase 1b cohort, to determine MTD (maximum tolerated dose) of nal-IRI (ONIVYDE®) in combination with Ramucirumab (Cyramza®) and TAS-102 (LONSURF®)\n* In phase II cohort, to evaluate disease objective response rate (ORR) of Ramucirumab (Cyramza®), nal-IRI (ONIVYDE®) in combination with TAS-102 (LONSURF®) Secondary Objectives\n* To evaluate disease control rate (DCR)\n* To evaluate progression-free survival (PFS)\n* To evaluate overall survival (OS)\n* To assess the safety profile\n* To study the blood biomarkers",[252,253,254],"Metastatic Gastric Adenocarcinoma","Second Line","Chemotherapy",[256,257,258],"nal-IRI (ONIVYDE)","TAS-102 (LONSURF)","Ramucirumab (Cyramza)",{"date":231,"type":35},{"date":261,"type":35},"2024-04-01",{"date":213,"type":21},{"name":41,"class":42},{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":22,"phases":273,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":281,"locationsCount":282},"100443016","phase-1-cabozantinib-and-lanreotide-as-treatment-for-gastroenteropancreatic-neuroendocrine-tumors-100443016","NCT05048901","Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors","A Phase I\u002FII Study Using Cabozantinib and Lanreotide as Treatment for Advanced Gastroenteropancreatic Neuroendocrine Tumors That Failed Molecular Targeted Therapies or Chemotherapy (SCALET)","Inclusion Criteria:\n\n1. Pathologically confirmed G1 or G2 NET of GEP origin with locally advanced or metastatic stage who failed to one line or more than one line of small molecular kinase inhibitor (mTOR inhibitor or other targeted kinase inhibitor) or W-D G3 NET of GEP origin with locally advanced or metastatic stage who failed to one line or more than one line of chemotherapy or small molecule kinase inhibitor.\n2. Radiologic progression within 12 months of entry\n3. Recovery to baseline or ≤ Grade 1 CTCAE v5 from toxicities related to any prior treatments, unless AE(s) are clinically non-significant and\u002For stable on supportive therapy.\n4. Age≥ 20 years old and ECOG Performance Status ≤ 1.\n5. Adequate organ and marrow function, based upon meeting all the following laboratory criteria within 14 days before first dose of study treatment:\n\n   1. Absolute neutrophil count (ANC) ≥ 1500\u002FµL without granulocyte colony- stimulating factor support.\n   2. White blood cell count ≥ 2500\u002FµL.\n   3. Platelets ≥ 100,000\u002FµL without transfusion.\n   4. Hemoglobin ≥ 9 g\u002FdL (≥ 90 g\u002FL).\n   5. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 3 x upper limit of normal (ULN). If there is liver metastasis, AST, ALT ≤ 5 x ULN. ALP ≤ 5 x ULN with documented bone metastases.\n   6. Total bilirubin ≤ 1.5 x ULN (for subjects with Gilbert's disease ≤ 3 x ULN).\n   7. Serum albumin ≥ 2.8 g\u002Fdl\n   8. (PT)\u002FINR or partial thromboplastin time (PTT) test \\\u003C 1.3 x the laboratory ULN\n   9. Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 50 mL\u002Fmin (≥ 0.5 mL\u002Fsec) using the Cockcroft-Gault equation:\n\n      Males: (140 - age) x weight (kg)\u002F(serum creatinine \\[mg\u002FdL\\] × 72) Females: \\[(140 - age) x weight (kg)\u002F(serum creatinine \\[mg\u002FdL\\] ×72)\\] × 0.85\n   10. Urine protein\u002Fcreatinine ratio (UPCR) ≤ 1 mg\u002Fmg (≤ 113.2 mg\u002Fmmol), or 24-h urine protein ≤ 1 g\n6. At least one measurable lesion according to RECIST 1.1 over non-locally treated site, such as RT, TAE (TACE), or RFA.\n7. Life expectancy greater than 12 weeks.\n8. Capable of understanding and complying with the protocol requirements and must have signed informed consent document.\n9. Female subjects of childbearing potential (i.e. less than or equal to 2 years post-menopause and not surgically sterile) and their partners must agree to use highly effective methods of contraception (that alone or in combination result in a failure rate of less than 1% per year when used consistently and correctly during the course of the study and for 4 months after the last dose of study treatment.\n\n   \\* Effective methods of birth control include:\n   * Hormonal contraception (oral, injectable, implantable, transdermal) plus a barrier method;\n   * intrauterine device (IUD) or intrauterine hormone-releasing system (IUS) plus a barrier method;\n   * bilateral tubal occlusion (females);\n   * vasectomized partner (males).\n10. Female subjects of childbearing potential must not be pregnant at screening. Female subjects are considered to be of childbearing potential unless one of the following criteria are met: documented permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman \\> 45 years-of-age in the absence of other biological or physiological causes. In addition, females \\\u003C 55 years-of-age must have a serum follicle stimulating (FSH) level \\> 40 mIU\u002FmL to confirm menopause). Note: Documentation may include review of medical records, medical examinations, or medical history interview by study site.\n\nExclusion Criteria:\n\n1. Prior use of cabozantinib. (prior use of lanreotide is acceptable)\n2. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks or 5 half-lives of the agent, whichever is longer, before first dose of study treatment.\n3. Receipt of any type of anticancer antibody (including investigational antibody) or systemic chemotherapy within 4 weeks before first dose of study treatment.\n4. Receipt of radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.\n5. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 4 weeks prior to first dose of study treatment after radiotherapy or at least 4 weeks prior to first dose of study treatment after major surgery (e.g., removal or biopsy of brain metastasis). Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of first dose of study treatment.\n6. Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:\n\n   1. Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).\n   2. Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor.\n7. The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n   a. Cardiovascular disorders:\n   1. Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias.\n   2. Uncontrolled hypertension defined as sustained blood pressure (BP) \\> 140 mm Hg systolic or \\> 90 mm Hg diastolic despite optimal antihypertensive treatment.\n   3. Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 6 months before first dose of study treatment.\n\n   \u003C!-- -->\n\n   1. Subjects with a diagnosis of incidental, subsegmental PE or deep vein thrombosis (DVT) within 6 months are allowed if stable, asymptomatic, and treated with a stable dose of permitted anticoagulation (see exclusion criterion #6) for at least 1 week before first dose of study treatment.\n   2. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:\n\n   i. The subject has evidence of tumor invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction.\n\n   ii. Abdominal fistula, GI perforation, bowel obstruction, or intra- abdominal abscess within 6 months before first dose of study treatment.\n\n   iii. Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment.\n8. Major surgery within 4 weeks prior to study enrolment. Complete wound healing within 2 weeks before treatment.\n9. Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose of study treatment.\n10. Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation.\n11. Lesions invading or encasing any major blood vessels.\n12. Other clinically significant disorders that would preclude safe study participation.\n\n    1. Serious non-healing wound\u002Fulcer\u002Fbone fracture.\n    2. Uncompensated\u002Fsymptomatic hypothyroidism.\n    3. Moderate to severe hepatic impairment (Child-Pugh B or C).\n13. Major surgery (e.g., laparoscopic nephrectomy, GI surgery, removal or biopsy of brain metastasis) within 4 weeks before first dose of study treatment. Minor surgeries within 2 weeks before first dose of study treatment. Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.\n14. Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 500 ms per electrocardiogram (ECG) within 14 days before first dose of study treatment \\[add reference for Fridericia formula\\].\n\n    Note: If a single ECG shows a QTcF with an absolute value \\> 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 min after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility.\n15. Pregnant or lactating females.\n16. Inability to swallow tablets.\n17. Previously identified allergy or hypersensitivity to components of the study treatment formulations.\n18. Any other active malignancy at time of first dose of study treatment or diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast, or stage 0-I colon or breast cancer treated by surgery only and without evidence of relapsed tumor.\n19. Mental status is not fit for clinical trial",{"count":272,"type":21},49,[249,24],"This is an Open-Label Phase I\u002FII Study of daily cabozantinib plus lanreotide every 4 w eeks to treat advanced G1-2 gastroentero-pancreatic neuroendocrine tumor (GEP-NET) patients who failed to one line or more than one line of small molecule kinase inhibitor or well-differentiated (W-D) G3 GEP-NET who failed to one line of small molecule kinase inhibitor or chemotherapy.",[276],"Neuroendocrine Tumors,Gastroenteropancreatic",{"date":231,"type":35},{"date":279,"type":35},"2021-09-17",{"date":92,"type":21},{"name":41,"class":42},11,{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":297,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":303},"100427705","the-research-plan-of-taiwan-precision-medicine-100427705","NCT04849481","The Research Plan of Taiwan Precision Medicine","The Research Plan of Taiwan Precision Medicine: Lung Cancer","Inclusion Criteria\n\n1. Ages 20 and above.\n2. Pathological reports showed adenocarcinoma, squamous cell carcinoma, large cell carcinoma, adenosquamous carcinoma, and sacromatoid carcinoma.\n3. For patients with squamous cell carcinoma, only never smokers and light smokers (less than 10 cigarettes per day) are indicated.\n4. For patients with advanced EGFR (-) and ALK (-) adenocarcinoma or other histological types regardless of EGFR\u002FALK status, treatment-naïve or failure to ≤ two lines of systemic treatment is allowed.\n5. For patients with advanced EGFR (+) or ALK (+) adenocarcinoma, failure to ≤ two lines of systemic treatment, including tyrosine kinase inhibitor is allowed.\n6. For patients with advanced EGFR exon 20 insertion\u002Fmutation (excluding T790M mutation) adenocarcinoma, failure to ≤ four lines of systemic treatment, including tyrosine kinase inhibitor is allowed.\n7. Reacquisition of tumor tissue after the failure of previous systemic treatment\n8. Willingness to provide the residual biopsy\u002Foperative slides.\n9. Life expectancy more than 3 months.\n10. Patients fully understand the protocol with the willingness to have regular follow-up.\n11. For patients with advanced EGFR exon 20 insertion\u002Fmutation (excluding T790M mutation) adenocarcinoma: if the patient had died before 2022\u002F07\u002F31, the waiver of Informed Consent Form(s) is allowed under the permission of Independent Ethics Committee\u002FInstitutional Review Board (IEC\u002FIRB). Exclusion Criteria\n\n1.Inability to cooperate by providing a complete medical history. 2.No available tumor tissues for genetic testing. 3.Undesirable compliance.",{"count":291,"type":21},550,"Non-small-cell lung cancer (NSCLC) is one of the top three most common cancers in Taiwan. Targetable driver mutations in NSCLC are more prevalent in Asian population compared to those in Western population, which offers chances to apply suitable targeted therapies worldwide. For patients who failed to the treatment of tyrosine kinase inhibitors (TKIs), the genetic mutations from next-generation sequencing (NGS) reports can serve as the reference of treatment selection. Moreover, the expression of PD-1\u002FPD-L1 serves as a helpful indicator for the response of immune checkpoint inhibitors (ICIs). On the other hand, patients with wild-type EGFR\u002FALK mutations and PD-L1-negative NSCLC who received chemotherapy had relative poorer survival than those received suitable targeted therapies and ICIs. To further elucidate the underlying molecular genomic aberrations, as well as the clinical demographics and therapeutic outcomes in above subpopulations, it is necessary to have a national, multi-centers and population-focused research project to collect data completely. Tumor tissue will be collected from advanced NSCLC patients with wild-type EGFR\u002FALK or with EGFR\u002FALK mutation after resistant to TKIs for next-generation sequencing analysis in a platform of data storage and sharing. The purpose of the precision medicine project is to establish tumor molecular profiling of specific NSCLC populations in Taiwan, to facilitate patients to have corresponding potential targeted therapeutics and suitable clinical trials, and to extend the median overall survival.",[294],"Non-small-cell Lung Cancer",[296],"non-small-cell lung cancer, next-generation sequencing",{"date":182,"type":35},{"date":299,"type":35},"2021-06-23",{"date":301,"type":21},"2030-12-31",{"name":41,"class":42},13,{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":311,"enrollmentInfo":312,"targetDuration":4,"studyType":22,"phases":314,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":324,"locationsCount":94},"100619996","precision-vibration-therapy-for-neuromuscular-and-functional-improvement-in-older-adults-and-stroke-survivors-100619996","NCT07351877","Precision Vibration Therapy for Neuromuscular and Functional Improvement in Older Adults and Stroke Survivors","Exploring the Clinical Benefits of Precision Vibration on Neuromuscular Induction, Proprioceptive Gain, Functional Enhancement, and Pain Relief in Older Adults and and Stroke Survivors","Inclusion Criteria:\n\nOlder Adults:\n\n* Meet two or more criteria of the Study of Osteoporotic Fractures (SOF) frailty index\n* Willing to participate in the study and comply with all study procedures\n* Able to wear and safely use the vibration device\n* Normal cognitive function (Mini-Mental State Examination \\[MMSE\\] score ≥ 23)\n* Presence of knee joint pain in the lower limbs\n\nStroke Survivors:\n\n* Clinical diagnosis of ischemic or hemorrhagic stroke confirmed by a physician\n* Clinically stable stroke condition (i.e., not in an acute or unstable phase)\n* Brunnstrom stage ≥ III for the affected limb\n* Cognitive ability sufficient to follow study procedures (MMSE score ≥ 23)\n* Modified Ashworth Scale (MAS) score \\\u003C 3 for the paretic limb\n* Able to sit safely and participate in vibration or rehabilitation sessions for up to 60 minutes per visit\n* Willing and able to comply with all study procedures and provide written informed consent\n\nExclusion Criteria:\n\nOlder Adults:\n\n* Acute or chronic neurological injury involving the upper or lower limbs within the past 6 months\n* Acute or chronic musculoskeletal injury involving the upper or lower limbs within the past 6 months\n* History of surgery on the upper or lower limbs within the past 6 months\n\nStroke Survivors:\n\n* Recurrent stroke during the current episode (i.e., acute re-stroke) or otherwise clinically unstable stroke presentation\n* Markedly elevated spasticity preventing isolated voluntary movement of the target limb (MAS score ≥ 3)\n* Hemianopsia or severe hemineglect that significantly interferes with task execution\n* Concomitant vestibular or cerebellar disorders that severely impair motor performance\n* Orthopedic or traumatic comorbidities causing significant pain or limiting safe participation during evaluation or intervention\n* Cognitive impairment attributable to stroke that precludes effective communication or adherence to the study protocol\n* Other neurological or psychiatric disorders judged likely to interfere with motor performance or study outcomes","95 Years",{"count":313,"type":21},80,[78],"To address muscle weakness, sensory degradation, functional decline, and pain caused by geriatric syndromes in older adults and stroke survivors, this project proposes a series of studies aimed at improving neuromuscular performance, muscle strength, proprioceptive gain, functional outcomes, and pain relief through the use of a precise vibration system.\n\nIn the first phase, a vibration exercise system will be implemented to recruit frail older adults and older adults with stroke for clinical trials. The goal is to verify the benefits of vibration intervention on limb muscle strength, proprioception, and movement function.\n\nIn the third phase, quantitative pain assessments and related scales will be used to evaluate chronic pain thresholds and affected regions in older adults and stroke survivors, and to validate the effectiveness of vibration intervention in alleviating their pain.",[109,317],"Stroke","2026-01-11",{"date":320,"type":35},"2026-01-20",{"date":322,"type":35},"2024-09-18",{"date":92,"type":21},{"name":41,"class":42},{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":102,"sex":17,"minAge":50,"maxAge":311,"enrollmentInfo":332,"targetDuration":4,"studyType":22,"phases":334,"briefSummary":335,"conditions":336,"keywords":339,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":346,"locationsCount":94},"100618362","chronic-wounds-and-blood-circulation-detection-100618362","NCT07330635","Chronic Wounds and Blood Circulation Detection","Constructing a Holistic Care New Model for Chronic Wounds and Blood Circulation Detection to Enhance Home Care Quality","Inclusion Criteria:\n\nGeneral criteria (applied to all participants):\n\nWillingness to participate in this study and comply with all study procedures. Able to perform basic physical activity and complete lower limb circulatory and functional assessments.\n\nNormal cognitive function sufficient to understand instructions and provide informed consent.\n\nGroup-specific criteria:\n\nYoung Adults (Control Group):Aged 20-40 years.No known chronic diseases or peripheral circulatory disorders.Considered healthy volunteers.\n\nOlder Adults (Healthy Elderly Group):Aged 65-95 years.No major chronic diseases affecting lower limb circulation.\n\nOlder Adults with Chronic Disease (Impaired Circulation Group):Aged 65-95 years.Diagnosed with one or more conditions known to impair peripheral circulation, including but not limited to peripheral arterial disease (e.g., atherosclerosis, thromboangiitis obliterans), chronic venous insufficiency (e.g., varicose veins), diabetes mellitus, hypertension, or hyperlipidemia.\n\nExclusion Criteria:\n\nRecent acute lower limb injury resulting in tissue exudation, swelling, or other conditions that prevent safe participation in the assessment or intervention procedures.",{"count":333,"type":21},425,[78],"Lower limb circulatory insufficiency and the associated chronic wounds are common health problems among the elderly. These issues not only affect the individual's mobility and quality of life but also potentially increase medical costs and caregiving expenses. Traditional treatment methods often employ medications to enhance blood circulation, but these clinical approaches have limited effectiveness and induce the risk of side effects. Utilizing exercise as an intervention strategy can help improve lower limb blood circulation in the elderly while reducing the side effects associated with medications. However, due to physical frailty, elderly individuals often cannot participate in high-intensity exercises to improve their circulatory performance.\n\nTherefore, this study will develop a lower limb circulation enhancement exercise system to improve the circulatory performance in individuals with poor lower limb circulation. It will compare the effects of lower limb circulation enhancement exercise, vibration exercise, and mixed exercise on improving blood circulation and functional performance in the elderly or individuals with poor lower limb circulation.\n\nParticipants will be randomly assigned into three groups: the lower limb circulation enhancement exercise group, the vibration exercise group, and the mixed exercise group. In addition, a separate group of young adults (control group) will serve as a reference for baseline comparisons. Initially, all participants will undergo a one-time exercise test, followed by a 12-week intervention. The lower limb circulation enhancement exercise group will perform a 30-minute leg press rowing exercise three times a week, while the vibration exercise group will engage in vibration exercise at the same frequency, and the mixed exercise group will perform group-based mixed exercise training at the same frequency. The young adult control group will not receive any intervention but will undergo the same assessments.\n\nOutcome evaluations before and after the intervention include lower limb blood perfusion monitoring, pain scales, and functional performance assessments.",[109,337,338,141],"Walking, Difficulty","Chronic Limb-Threatening Ischemia",[340,116,141],"Poor Lower Limb Circulation","2025-12-29",{"date":155,"type":35},{"date":344,"type":35},"2024-09-04",{"date":92,"type":21},{"name":41,"class":42},{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":74,"enrollmentInfo":355,"targetDuration":4,"studyType":22,"phases":357,"briefSummary":358,"conditions":359,"keywords":362,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":4},"100606577","internet-based-cognitive-behavioral-therapy-with-treatment-as-usual-for-generalized-anxiety-disorder-and-major-depressive-disorder-in-taiwan-icbt-tw-100606577","NCT07177365","Internet-Based Cognitive Behavioral Therapy With Treatment as Usual for Generalized Anxiety Disorder and Major Depressive Disorder in Taiwan (ICBT-TW)","ICBT Clinical Validation - A Clinical Study on Internet-based Cognitive Behavioral Intervention for Generalized Anxiety Disorder and Major Depressive Disorder","ICBT-TW","Inclusion Criteria:\n\n* Age between 20 and 65 years.\n* Diagnosis of Generalized Anxiety Disorder (GAD) confirmed by a psychiatrist.\n* Diagnosis of Major Depressive Disorder (MDD) confirmed by a psychiatrist, without acute suicidal risk (screened by PHQ-9 Item 9; score of 3 requires further clinical assessment to exclude active suicidal plan or recent self-harm).\n\nExclusion Criteria:\n\n* For GAD ICBT participants\n\n  * Current or past history of obsessive-compulsive disorder, panic disorder, bipolar disorder, eating disorder, schizophrenia, or substance abuse.\n  * Severe depressive symptoms impairing daily functioning.\n  * Current suicidal ideation.\n  * Experiencing acute life stressors (e.g., domestic violence, ongoing treatment for serious physical illness).\n  * Currently receiving psychological counseling or psychotherapy.\n  * Other serious factors limiting participation (e.g., intellectual disability, significant cognitive impairment, severe vision or hearing impairment).\n* For MDD ICBT participants\n\n  * Diagnosis of bipolar disorder, eating disorder, schizophrenia, psychotic symptoms, or substance abuse.\n  * Current suicidal ideation or recent self-harm (PHQ-9 Item 9 score of 3 triggers further assessment; exclusion if active suicidal plan or recent self-harm present).\n  * Experiencing acute life stressors (e.g., domestic violence, ongoing treatment for serious physical illness).\n  * Currently receiving psychological counseling or psychotherapy.\n  * Other serious factors limiting participation (e.g., intellectual disability, significant cognitive impairment, severe vision or hearing impairment).",{"count":356,"type":21},120,[78],"This study aims to evaluate the effectiveness of internet-based cognitive behavioral therapy (ICBT) combined with treatment as usual (TAU) for adults diagnosed with generalized anxiety disorder (GAD) or major depressive disorder (MDD) in Taiwan.\n\nCBT is a proven treatment for anxiety and depression, but traditional face-to-face sessions require frequent clinic visits, which may be costly and time-consuming. ICBT delivers similar therapy content online, allowing participants to complete sessions at their own pace, reducing barriers such as travel and scheduling.\n\nA total of 160 participants will be randomly assigned to receive either TAU alone or TAU plus an 8-week ICBT program delivered via a secure national research platform. The program includes 12 online modules covering cognitive restructuring, emotion regulation, and behavioral activation techniques. Participants will complete assessments before, during, and after the program, with follow-up at 3 months.\n\nThe results will help determine whether ICBT can improve symptoms, enhance treatment accessibility, and support the integration of digital mental health interventions into clinical practice in Taiwan.",[360,361],"Generalized Anxiety Disorder (GAD)","Major Depressive Disorder (MDD)",[363,364,365,366,367,368,369,370,371,372],"Internet-Based Cognitive Behavioral Therapy","ICBT","Digital Mental Health","Online Therapy","Randomized Controlled Trial","Cognitive Restructuring","Mindfulness","Self-Compassion","Taiwan","Treatment as Usual (TAU)","2025-09-17",{"date":375,"type":35},"2025-09-22",{"date":377,"type":21},"2025-09-20",{"date":379,"type":21},"2026-06-30",{"name":41,"class":42},{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":102,"sex":17,"minAge":103,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":22,"phases":391,"briefSummary":392,"conditions":393,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":405},"100607243","effects-of-mindfulness-or-brain-stimulation-intervention-for-late-life-adults-in-taiwan-urban-and-rural-areas-100607243","NCT07186023","Effects of Mindfulness or Brain Stimulation Intervention for Late-life Adults in Taiwan Urban and Rural Areas","Intervention Evaluation for Late-life Depression in Taiwan Urban and Rural Areas: Long-term Tracking and Prediction of Non-pharmaceutical Interventions by Smart AI Technologies","PredictNPI","Inclusion Criteria for individuals participating in mindfulness-based Interventions:\n\n* Literate or have received an education above the elementary level.\n* Have normal or corrected vision and hearing, able to communicate and understand explanations.\n* Right-handed individuals as assessed by the Edinburgh Handedness Inventory.\n\nExclusion Criteria for individuals participating in mindfulness-based Interventions:\n\n* Individuals with dementia, stroke, cerebrovascular disease, brain injury, epilepsy, or Parkinson's disease.\n* Individuals with neurological system disorders.\n* Individuals with alcohol or drug dependence.\n* Individuals with other major physical illnesses, such as diabetes, heart failure, or endocrine abnormalities, or those who have experienced an acute myocardial infarction within the past three months.\n* Individuals with metal objects in the body that cannot undergo magnetic resonance imaging (MRI), such as cardiac pacemakers, vascular clips, hearing aids, artificial joints, steel pins, etc.\n* Individuals with Claustrophobia.\n* Individuals in pregnancy or possibility of pregnancy.\n\nInclusion Criteria for individuals participating in brain stimulation Intervention:\n\n* Individuals diagnosed with major depressive disorder by psychiatrists according to the Diagnostic and Statistical Manual, and who can cooperate with the psychiatric outpatient clinic regulations.\n* Literate or have received an education above the elementary level.\n* Have normal or corrected vision and hearing, able to communicate and understand explanations.\n* Right-handed individuals as assessed by the Edinburgh Handedness Inventory.\n* Individuals are prescribed brain stimulation therapy by clinical physicians.\n\nExclusion Criteria for individuals participating in brain stimulation Intervention:\n\n* Individuals with dementia, stroke, cerebrovascular disease, brain injury, epilepsy, or Parkinson's disease.\n* Individuals with neurological system disorders.\n* Individuals with alcohol or drug dependence.\n* Individuals with other major physical illnesses, such as diabetes, heart failure, or endocrine abnormalities, or those who have experienced an acute myocardial infarction within the past three months.\n* Individuals with metal objects in the body that cannot undergo magnetic resonance imaging (MRI), such as cardiac pacemakers, vascular clips, hearing aids, artificial joints, steel pins, etc.\n* Individuals with Claustrophobia.\n* Individuals in pregnancy or possibility of pregnancy.",{"count":390,"type":21},124,[78],"This randomized controlled trial will examine the effects of mindfulness-based interventions and brain stimulation interventions on cognitive function and psychological well-being in older adults. The study will employ a comprehensive assessment approach incorporating psychological evaluations, behavioral assessments, psychophysiological measurements, and neuroimaging analyses to characterize the outcome of nonpharmaceutical interventions in improving geriatric well-being or reducing depression severity.",[394,395,396,369,397],"Late-Life Adults","Late-Life Prodromal Depression","Late-Life Depression","Brain Stimulation Intervention","2025-09-15",{"date":375,"type":35},{"date":401,"type":35},"2025-08-01",{"date":403,"type":21},"2028-12",{"name":41,"class":42},2,{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":412,"eligibilityCriteria":413,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":22,"phases":416,"briefSummary":417,"conditions":418,"keywords":420,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":431},"100604577","phase-2-cabozantinib-for-progressive-hcc-post-first-line-immuno-oncologic-combination-therapy-100604577","NCT07151326","Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy","A Phase II, Single-arm, Multi-center Trial of Cabozantinib for Progressive Hepatocellular Carcinoma (HCC) Post-first-line Immuno-oncologic Combination Therapy (CAPIO Study)","CAPIO","Inclusion Criteria:\n\n1. Understood and signed the informed consent form\n2. Ability to comply with all protocol requirements\n3. Age ≥ 18 years when signing informed consent form\n4. Diagnosis of HCC confirmed by histology\n5. Disease progression following prior first-line ICI-based combination therapy (only atezolizumab plus bevacizumab or tremelimumab plus durvalumab is permitted. Any liver-directed locoregional therapies administered during the treatment period of the first-line ICI-based combination therapy are allowed.\n6. Disease that is not amenable to curative surgical and\u002For locoregional therapies (e.g. surgery, transplant, radiofrequency ablation)\n7. At least one measurable target lesion (per RECIST v1.1) that has not been previously treated with local therapy (e.g., radiofrequency ablation, cryoablation, transarterial embolization, transaraterial chemoembolization, radiotherapy, etc.) or, if the target lesion is within the field of previous local therapy, has subsequently progressed in accordance with RECIST v1.1.\n8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n9. Child-Pugh A of liver reserve\n10. Adequate hematologic and biochemical profiles:\n\n    * White blood cells (WBC) ≥ 3,000\u002FμL and absolute neutrophil count (ANC) ≥ 1,200\u002FμL without granulocyte colony-stimulating factor support within 1 week before registration\n    * Platelets (PLT) ≥ 60,000\u002FμL without transfusion within 1 week before registration\n    * Hemoglobin (Hb) ≥ 8 g\u002FdL without transfusion within 1 week before registration\n    * Serum creatinine (Cr) ≤ 1.5 × upper limit of normal (ULN) or calculated creatinine clearance ≥ 40 mL\u002Fmin (using the Cockroft-Gault equation)\n    * Aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP) ≤5 × ULN\n    * Serum total bilirubin (T-Bil) ≤ 2× ULN\n    * Serum albumin (Alb) \\> 28 g\u002FL (2.8 g\u002FdL)\n    * Urinalysis for proteinuria \\\u003C 2+. Patients discovered to have ≥ 2+ proteinuria on urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate \\\u003C 1 g of protein in 24 hours.\n11. Recovery to grade 1 from AEs related to any prior treatments, unless the AEs are clinically nonsignificant and\u002For stable on supportive therapy\n12. Subjects with chronic hepatitis B virus (HBV) infection (defined as HBV surface antigen. positive; HBsAg+) must receive antiviral therapy with nucleoside analogs according to the local guidance throughout the study\n13. Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the study and for 4 months after the last dose of study treatment\n14. Life expectancy of 12 weeks or longer\n\nExclusion Criteria:\n\n1. Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma\n2. Prior cabozantinib treatment\n3. Any systemic anti-cancer therapy administered after discontinuation of the first-line immune checkpoint inhibitor-based combination\n4. Prior liver-directed locoregional therapy administered within 4 weeks before registration\n5. Any liver-directed locoregional therapy performed after progression with the first-line immune checkpoint inhibitor-based combination, but palliative radiotherapy for symptomatic bone metastasis is allowed\n6. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 3 months before registration\n7. Presence of tumor thrombosis or invasion in inferior vena cava (IVC), a major arterial blood vessel (e.g., pulmonary artery or aorta) or heart\n8. Subjects with HBV DNA \\> 2000 IU\u002FmL or detectable hepatitis C virus (HCV) RNA\n9. Subjects refuse to provide tumor biopsy specimens within 4 weeks before registration\n10. Concomitant anticoagulation, at therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, low molecular weight heparin (LMWH), thrombin or coagulation factor X (FXa) inhibitors.\n\n    (Note: Low dose aspirin for cardioprotection (per local applicable guidelines), low-dose warfarin (≤ 1 mg\u002Fday), and low dose LMWH (e.g. 40 mg Enoxaparin) for prophylaxis of venous thromboembolism are permitted)\n11. Subjects with uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n    * Cardiovascular disorders including symptomatic congestive heart failure, unstable angina pectoris, or serious cardiac arrhythmias\n    * Uncontrolled hypertension defined as sustained systolic blood pressure (BP) \\> 150 mm Hg, or diastolic BP \\> 100 mm Hg despite optimal antihypertensive treatment\n    * Stroke (including transient ischemic attack), myocardial infarction, or other ischemic event within 6 months\n    * Thromboembolic event within 3 months. (Note: Subjects with thromboses of portal\u002Fhepatic vasculature attributed to underlying liver disease and\u002For liver tumour are eligible)\n    * Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation\u002Fbleeding:\n    * Tumours invading the GI tract, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis or acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction\n    * Abdominal fistula, GI perforation, bowel obstruction, intra-abdominal abscess within 6 months\n12. Major surgery within 2 months before registration. Complete healing from major surgery must have occurred 1 month before registration. Complete healing from minor surgery (e.g., simple excision, tooth extraction) must have occurred at least 7 days before registration\n13. Clinically significant bleeding risk including the following within 3 months before registration: upper GI bleeding (including gastroesophageal varices bleeding), hematuria, hemoptysis of \\>0.5 teaspoon (\\>2.5 mL) of red blood, or other signs indicative of pulmonary hemorrhage, or history of other significant bleeding if not due to reversible external factors\n14. Moderate or severe ascites (radiologically detected but clinically insignificant ascites without any diuretics or palliative paracentesis is allowed)\n15. Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 500 ms within 4weeks before registration (Note: If the QTcF is \\> 500 ms in first ECG, a total of 3 ECGs should be performed. If the average of these 3 consecutive results for QTcF is ≤ 500 ms, the subject meets eligibility)\n16. Previously identified allergy or hypersensitivity to components of the study treatment formulations\n17. Inability in swallowing tablets\n18. Pregnant or lactating females\n19. Diagnosis of another malignancy within 2 years before registration, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy\n20. Other clinically significant disorders that are judged by investigators to be unsuitable for the clinical trial",{"count":415,"type":21},60,[24],"1. To investigate the efficacy and safety of cabozantinib in patients with progressive HCC after ICI-based combination treatment.\n2. To explore potential tissue and peripheral blood biomarkers associated with clinical benefits of cabozantinib, and resistance mechanisms of prior ICI and cabozantinib.",[419],"Hepatocellular Carcinoma (HCC)",[421,422,423],"Tyrosine kinase inhibitor","Immune checkpoint inhibitor","Multikinase inhibitors",{"date":425,"type":35},"2025-09-03",{"date":427,"type":21},"2025-09",{"date":429,"type":21},"2028-06",{"name":41,"class":42},9,{"id":433,"slug":434,"hasResults":11,"nctId":435,"briefTitle":436,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":440,"conditions":441,"keywords":443,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":451,"locationsCount":237},"100487079","a-taiwanese-oncogenetic-panel-and-integrated-clinical-data-registry-study-for-diffuse-glioma-100487079","NCT05622409","A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma","Inclusion Criteria:\n\n1. Pathological confirmation or suggestion of adult-type diffuse gliomas A. Diagnosis includes glioblastoma, astrocytoma, oligodendrocytoma that is listed in ATDG category per WHO criteria.\n\n   B. Gliomas that are preferred as ATDGs from pathological and clinical views, but not given for confirmed diagnosis.\n2. Willingness to provide archival or newly obtained tumor tissues for current study proposal.\n3. Age equal or more than 20 years old (inform consent).\n4. Life expectancy more than 3 months.\n5. Patients fully understand the protocol with the willingness to have regular follow-up.\n6. Additional criteria for individual arms A. \\[Arm 1\\] Within 2 months after surgery for primary tumor. B. \\[Arm 2\\] Total resection of primary tumors with tissue samples available for test.\n\nC. \\[Arm 3\\] (1) Total resection of primary tumors with the paired primary and recurrent tissue samples available for test. (2) IDH test suggesting wild-type.\n\nExclusion Criteria:\n\n1. Gliomas diagnosed or preferred as other categories than ATDGs, such as pediatric-type diffuse gliomas, circumscribed astrocytic gliomas, and others.\n2. Inability to cooperate by providing a complete medical history.\n3. Patients disagree to provide archived tumor samples.\n4. Undesirable compliance.\n5. Having a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervical carcinoma in situ) that have undergone potentially curative therapy are not excluded.",{"count":439,"type":21},250,"Glioma is a major histological subtype of primary malignant brain tumors in Taiwan, with distinct epidemiological, clinical, and pathological features comparing to the other common cancer diseases. The disease rarely appears with metastatic disease at diagnosis, and with the most malignant subtype, glioblastoma, occurs with preference in mid- to old-age. For decades, primary malignant brain tumors has been known as one of the most desperate disease without successful improvement regarding of the treatment. Surgical resection is the principle for the primary treatment of gliomas. Chemotherapy and radiotherapy are often applied to patients for adjuvant therapy of surgery to pursue the treatment effect. Disappointedly, vast majority of the patients would eventually develop disease recurrence, leaving only limited choice for salvage treatment thereafter. The prognosis of these patients remains desperate, and thus a better understanding of this deadly disease is crucial for finding better therapeutic strategies for these patients.",[442],"Primary Malignant Brain Tumors",[444,60,61],"adult-type diffuse gliomas","2025-08-31",{"date":447,"type":35},"2025-09-08",{"date":449,"type":35},"2022-12-29",{"date":301,"type":21},{"name":41,"class":42},{"id":453,"slug":454,"hasResults":11,"nctId":455,"briefTitle":456,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":461,"conditions":462,"keywords":464,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":472,"leadSponsor":474,"locationsCount":431},"100603572","taiwanese-anaplastic-thyroid-cancer-registry-100603572","NCT07138261","Taiwanese Anaplastic Thyroid Cancer Registry","TATC","Inclusion Criteria:\n\n1. Pathologically or cytologically confirmed ATC and diagnosed after 2015.\n2. Capable of understanding and complying with the protocol requirements and signed informed consent. The dead patient can be enrolled without signed informed consent and they were dead before 2025.6.30.\n\nExclusion Criteria:\n\n1. Inability and unwillingness to give informed consent except dead patient.\n2. Patients refuse for collection of clinical data and follow up.",{"count":460,"type":21},100,"Primary treatment strategies for ATC have included surgical resection combined with radiotherapy, chemotherapy, or concurrent chemoradiation therapy. Despite these aggressive approaches, disease recurrence or progression remains frequently observed. Recent advances in molecular diagnostics and targeted therapy development have expanded treatment options for ATC patients with actionable genetic alterations, such as BRAF mutations or NTRK fusions. Nevertheless, for patients lacking identifiable targetable mutations, therapeutic options remain limited and clinical outcomes are poor. To address this unmet clinical need, the investigators aim to analyze baseline characteristics, treatment outcomes, and biomarker profiles from a larger cohort of ATC patients, with the goal of identification of predictive biomarkers and potential therapeutic targets. Given the rarity of ATC, conducting comprehensive studies at a single institution is challenging. Therefore, the investigators propose to establish a multi-center registry to systematically collect clinical data and tumor specimens from ATC patients.",[463],"Thyroid Carcinoma, Anaplastic",[465,466,467],"Anaplastic thyroid cancer","Genetic aberrations in anaplastic thyroid cancer","Treatment for anaplastic thyroid cancer","2025-08-17",{"date":470,"type":35},"2025-08-22",{"date":211,"type":21},{"date":473,"type":21},"2035-12-30",{"name":41,"class":42},{"id":476,"slug":477,"hasResults":11,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":482,"targetDuration":484,"studyType":53,"phases":4,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":494,"locationsCount":94},"100331963","observational-registry-data-on-gist-patients-100331963","NCT03602092","Observational Registry Data on GIST Patients","The Observational Registry: Nationwide Data Collection on Gastrointestinal Stromal Tumors (GISTs) Patients (Taiwan GISTs Registry)","Inclusion Criteria:\n\n1. Patients diagnosed with Gastrointestinal Stromal Tumor\n2. ≥20 years old\n3. Histology-confirmed GIST between 01 January 2010 and 31 December 2020.\n4. Patient with prospective data collection: Willing to provide singed inform-consent as per local regulatory requirements.\n\nExclusion Criteria:\n\n1. Inability and unwillingness to give informed consent if required by site ethic committee.\n2. Patient that is unlikely candidate to obtain long-term follow-up information for reasons of unavailability or with severe concomitant illnesses per investigator judgement",{"count":483,"type":21},3000,"7 Years","This is a longitudinal, multi-center, registry study, collecting data via a web-based portal in patients with GIST (Gastrointestinal Stromal Tumor) from hospitals in Taiwan.",[487],"Gastrointestinal Stromal Tumors","2025-05-19",{"date":490,"type":35},"2025-05-22",{"date":492,"type":35},"2018-10-16",{"date":37,"type":21},{"name":41,"class":42},{"id":496,"slug":497,"hasResults":11,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":102,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":503,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":504,"conditions":505,"keywords":507,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":517,"locationsCount":518},"100589283","the-registry-study-of-genetic-alterations-of-melanoma-in-taiwan-100589283","NCT06952400","The Registry Study of Genetic Alterations of Melanoma in Taiwan","T1622 The Registry Study of Genetic Alterations of Melanoma in Taiwan","Melanoma","Inclusion Criteria:\n\n1. Age \\> 18 years old\n2. Pathologically confirmed melanoma. (Patients with additional malignancies requiring treatment or follow-up are allowed. Only treatment for melanoma should be recorded).\n3. ECOG performance status \\\u003C 3\n4. Cohort 1(early acral melanoma): melanoma, stage I\u002FII; Cohort 2 (locally advanced acral melanoma): melanoma, stage III, resectable; and Cohort 3 (advanced): unresectable \u002F metastatic melanoma, stage III\u002FIV or recurrent melanoma (unresectable). Staging is based on AJCC Cancer Staging System 8th edition). The patients with advanced melanoma with available comprehensive NGS report are included in cohort 4.\n5. Willingness to provide archival or newly obtained tumor tissues for this study proposal\n6. Life expectancy more than 3 months -\n7. Patients fully understand the protocol with the willingness to have regular follow-up\n\nExclusion Criteria:\n\n1. Inability to cooperate by providing a complete medical history\n2. No available tumor tissues for genetic testing (archived tissue sampling more than 5 years from screening date)\n3. Undesirable compliance (Mental status is not fit for further treatment or data collection.)",{"count":439,"type":21},"Cutaneous melanoma is the most aggressive malignancy in skin cancers. Cutaneous melanoma is a rare disease in Taiwan with an incidence rate of around 1\u002F100,000. Acral lentiginous melanoma is the most common subtype and comprises more than half of cutaneous melanoma in Asia including Taiwan but only 1% in Caucasians. In addition, mucosal melanoma accounts for more than 20% of malignancy melanoma in Taiwan but only 1% in Caucasians. Acral and mucosal melanomas have distinct epidemiological, clinical, pathological and genetic features from non-acral melanoma which is commonly seen in Western countries. Comparing with melanoma in Caucasians, Asian melanoma has higher recurrence rate after primary surgery, lower response rate to immunotherapy, and shorter progression-free survival for immunotherapy and targeted therapy leading generally poor survival outcomes regardless stage.",[506],"Primary Melanoma of the Extremity",[60,508,509,510],"acral melanoma","mucosal melanoma","cutaeous melanoma","2025-05-01",{"date":513,"type":35},"2025-05-06",{"date":515,"type":35},"2022-08-22",{"date":301,"type":21},{"name":41,"class":42},16,{"id":520,"slug":521,"hasResults":11,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":525,"eligibilityCriteria":526,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":527,"enrollmentInfo":528,"targetDuration":4,"studyType":22,"phases":530,"briefSummary":531,"conditions":532,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":540,"locationsCount":4},"100428215","phase-1-a-phase-iii-study-of-diffuse-large-b-cell-lymphoma-100428215","NCT04856137","A Phase I\u002FII Study of Diffuse Large B-cell Lymphoma","A Phase I\u002FII Study of Relapse\u002FRefractory Diffuse Large B-cell Lymphoma","DLBL","Inclusion Criteria:\n\n1. Patients with relapsed\u002Frefractory CD20+ diffuse large B-cell lymphoma.\n2. Age greater than 20 years and younger than 75 years old.\n3. Measurable disease\n4. Patients must have an ECOG performance status of less than or equal to 2.\n5. Patients must have recovered from toxic effects of all prior therapy before entering onto study.\n6. A treatment of drug-free interval of at least 3 weeks since the last dose of chemotherapy is required.\n7. More than 4 weeks since prior radiotherapy is required.\n8. Adequate bone marrow function\n9. Adequate renal function with calculated glomerular filtration rate \\> 15 mL\u002Fmin\n10. Patients must have adequate liver function\n11. All patients must sign a document of informed consent indicating their awareness of the investigational nature and the risks of the study.\n\nExclusion Criteria:\n\n1. Patients who have prior treatment with ruxolitinib or taxane for DLBCL.\n2. Pregnant or breast-feeding females.\n3. Active or uncontrolled infection.\n4. Life expectancy \\\u003C 6 months\n5. Patients with brain or leptomeningeal metastases.\n6. Known hypersensitivity to ruxolitinib or paclitaxel\n7. Grade III peripheral neuropathy secondary to prior to therapy\n8. Second malignancy, except indolent cancers not on active anti-cancer therapy.","75 Years",{"count":529,"type":21},74,[249,24],"For continuous variables, mean, median, minimum, and maximum will be used for the descriptive purpose. For categorical variables, frequency and percentage will be used for descriptive statistics. The variables of OS will be estimated by the Kaplan-Meier method. Differences between groups will be calculated using the log-rank test for univariate analysis. Cox's proportional hazards model will be employed to test independent prognostic factors. All calculations will be performed using the Statistical Package of Social Sciences software, version 17.0 (SPSS, Inc., Chicago, IL, USA). The level of statistical significance will be set at 0.05 for all tests.",[533],"Refractory Diffuse Large B-cell Lymphoma","2021-04-19",{"date":536,"type":35},"2021-04-23",{"date":538,"type":21},"2021-05-01",{"date":213,"type":21},{"name":41,"class":42},""]